Lumedx Corp. announced that it has been selected to provide a cardiovascular information system (CVIS) for four CoxHealth hospitals. Based in Springfield, Mo., CoxHealth chose the Lumedx HealthView platform for its robust analytics software and because the company offers the ability to integrate disparate systems with a single sign-on.

March 8, 2016 — phenox GmbH announced participation in the SITS Open clinical trial, where pREset and pREset LITE thrombectomy devices have been included in the study device portfolio. pREset is one of only three devices to be used in the study.

Fluoroscopy makes guiding a catheter through a blood vessel possible. However, fluoroscopy, a form of real-time moving X-ray, also exposes the patient to radiation. Now, a University of Missouri School of Medicine researcher has evaluated technology that may be used to replace fluoroscopy, eliminating the need for X-ray during cardiac ablation procedures.

Biotronik announced publication of results from the BIOSCIENCE trial in the journal EuroIntervention. The study’s authors suggest the Orsiro hybrid drug-eluting stent (DES) may have an advantage over Xience Prime/Xpedition in treating ST-segment elevation myocardial infarction (STEMI) patients. STEMI is a potentially fatal type of heart attack caused by a prolonged obstruction of blood supply in the heart. Every year nearly 250,000 people experience STEMI heart attacks.

Women undergoing transcatheter aortic valve replacement (TAVR) have better survival rates than men at one year, according to a study published in Annals of Internal Medicine. These results are the opposite of those seen in surgical aortic valve replacement (SAVR), for which female sex has been shown to be associated with poorer outcomes.

At the Houston Aortic Symposium, W. L. Gore & Associates, Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) approval of the Gore Excluder Iliac Branch Endoprosthesis (IBE). The approval makes it the first off-the-shelf aortic branch device approved in the United States and the only device indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms.

Medtronic plc announced the first patients enrolled in the Evolut R FORWARD Clinical Study to evaluate performance outcomes using the CoreValve Evolut R System in everyday clinical practice.

Pacific Northwest Endovascular Conference (PNEC)

March 4, 2016 — Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the Acuity X4 quadripolar left ventricular (LV) leads.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now